Canine Parvovirus Monoclonal Antibody receives conditional USDA approval for passive immunity

Elanco Animal Health Incorporated announced today that its Canine Parvovirus Monoclonal Antibody (CPMA) has become the first US Department of Agriculture conditionally approved treatment that targets canine parvovirus (parvo). This conditional approval means the CPMA can be used for passive immunity to prevent parvo in puppies that have been exposed to the virus, which will expand the potential of protecting dogs from this disease that affects more than 330,000 puppies annually.2

“We understand that pet owners and veterinarians are navigating rising costs and financial uncertainty right now, which is why we’re focused on making CPMA even more accessible to every puppy that needs it,” Chris George, DVM, infectious disease expert at Elanco Animal Health, said in the organizational release.1 “The label expansion to include passive immunity, in addition to our $200 rebate program, and sampling programs to shelters and clinics in high parvovirus areas further advances our mission to defend puppies and defeat parvo, delivering value and peace of mind to veterinarians and pet owners alike.”

According to the release, the expanded product label means that the dogs that have been exposed to the deadly virus can be protected, including environments where resources can often be constricted, such as shelters. In a study conducted by Elanco, when dogs 8 weeks or older were given a prophylactic dose, CPMA was 100% effective in the passive immunity of these healthy dogs.1

A shelter in Florida recently treated and saved the lives of 27 parvo puppies through CPMA, the largest recorded group to be saved through the monoclonal antibody treatment to date, according to Elanco.1 Some of the puppies in the litter are now up for adoption and are "thriving" in the shelter.

Through its Defend Puppies. Defeat Parvo. campaign, Elanco shared that it expanded CPMA’s availability by donating more than $3 million worth of the product to 2300 clinics and shelters located in high-parvo areas across the US. This program reportedly helped shelters, veterinary professionals, and clients get better access to the lifesaving treatment. Through the expanded label, CPMA now has the potential to save thousands of puppies from parvo.

“We understand that pet owners and veterinarians are navigating rising costs and financial uncertainty right now, which is why we’re focused on making CPMA even more accessible to every puppy that needs it,” George said.

“The label expansion to include passive immunity, in addition to our $200 rebate program, and sampling programs to shelters and clinics in high parvovirus areas further advances our mission to defend puppies and defeat parvo, delivering value and peace of mind to veterinarians and pet owners alike.”

References

1. Elanco announces milestones expanding access to Canine Parvovirus Monoclonal Antibody (CPMA) to veterinarians and shelters across the country. News release. Elanco Animal Health Incorporated. June 26, 2025. Accessed June 26, 2025.
2. New data reveals Elanco’s Canine Parvovirus Monoclonal Antibody treatment significantly improves puppy survival rates and relieves operational stress in veterinary clinics. News release. Elanco Animal Health Incorporated. October 15, 2024. Accessed June 26, 2025. https://www.elanco.com/us/newsroom/press-releases/new-data-reveals-elanco-canine-parvovirus-monoclonal-antibody-treatment-significantly-improves-puppy-survival-rates